PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Sofosbuvir - Hepatitis C
PAD Profile : Sofosbuvir - Hepatitis C
Keywords :
Hep C, NICE, antiviral
Brand Names Include :
Sovaldi
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Boceprevir
- Ribavirin
- Daclatasvir
- Glecaprevir/pibrentasvir
- Dasabuvir
- Elbasvir
- Nitazoxanide
- Paritaprevir
- Setrobuvir
- Sofosbuvir, daclatasvir and ribavirin
- Sofosbuvir and velpatasvir
- Asunaprevir and daclatasvir
- Beclabuvir
- Filibuvir
- Elbasvir/grazoprevir
- Ledipasvir/sofosbuvir
- Paritaprevir/ritonavir/ombitasvir
- Ritonavir
- Peginterferon alfa
- Sofosbuvir/velpatasvir/voxilaprevir
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
03 March 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Funded by NHS England. Treatment should remain with the specialist (RED) hospital only drug.
Associated BNF Codes
05. Infections
05.03.03. Viral hepatitis